Perfil
Claire J.
Lockey formerly worked at Titan Pharmaceuticals, Inc., as Vice President-Regulatory Affairs, Connetics Corp., as Principal, Tricida, Inc., as Chief Development Officer & Senior Vice President from 2016 to 2019, FibroGen, Inc., as Vice President-Regulatory Affairs from 2003 to 2010, Layton BioScience, Inc., as Principal, Relypsa, Inc., as Senior Vice President-Regulatory Affairs from 2012 to 2015, Synergia LLC, as Principal from 1985 to 1995, and Gore Hybrid Technologies, Inc., as Principal.
Ms. Lockey received her undergraduate degree from Boston University.
Antiguos cargos conocidos de Claire J. Lockey.
| Empresas | Cargo | Fin |
|---|---|---|
| TRICIDA, INC. | Corporate Officer/Principal | 01/11/2019 |
| RELYPSA INC | General Counsel | 01/11/2015 |
| FIBROGEN, INC. | General Counsel | 01/01/2010 |
| Synergia LLC | Corporate Officer/Principal | 01/01/1995 |
| Gore Hybrid Technologies, Inc. | Corporate Officer/Principal | - |
Formación de Claire J. Lockey.
| Boston University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| TITAN PHARMACEUTICALS, INC. | Health Technology |
| TRICIDA, INC. | Health Technology |
| FIBROGEN, INC. | Health Technology |
| Empresas privadas | 5 |
|---|---|
Connetics Corp.
 Connetics Corp. BiotechnologyHealth Technology Connetics Corp. develops and commercializes dermatology products. The firm offers remedies for psoriasis in adults, eczema, seborrheic dermatitis, and acne. The company was founded in 1993 and is headquartered in Palo Alto, CA. | Health Technology |
| Layton BioScience, Inc. | |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
| Synergia LLC | |
| Gore Hybrid Technologies, Inc. |
- Bolsa de valores
- Insiders
- Claire J. Lockey
